Stryker (SYK) 10-Q 24 Apr 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014
Document and Entity Information	'
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	31-Mar-14
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q1
Trading Symbol	'SYK
Entity Registrant Name	'STRYKER CORP
Entity Central Index Key	'0000310764
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	379,093,934

Consolidated_Statements_Of_Ear

Consolidated Statements Of Earnings (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net sales	$2,305	$2,190
Cost of sales	769	713
Gross profit	1,536	1,477
Research, development and engineering expenses	150	129
Selling, general and administrative expenses	1,205	916
Intangible asset amortization	45	32
Restructuring charges	5	14
Total operating expenses	1,405	1,091
Operating income	131	386
Other income (expense), net	-24	-11
Earnings before income taxes	107	375
Income taxes	37	71
Net earnings	$70	$304
Net earnings per share of common stock:	'	'
Basic net earnings per share of common stock	$0.19	$0.80
Diluted net earnings per share of common stock	$0.18	$0.79
Weighted-average shares outstanding—in millions:	'	'
Basic	378.2	379.7
Net effect of dilutive employee stock options	4.4	3.3
Diluted	382.6	383
Anti-dilutive shares excluded from the calculation of net effect of dilutive employee stock options	2.5	5.1

Consolidated_Statement_of_Comp

Consolidated Statement of Comprehensive Income (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net earnings	$70	$304
Unrealized gains (losses) on securities, net of tax (expense) benefit of $(0) and $0, respectively	3	-1
Unfunded pension (losses) gains, net of tax benefit (expense) of $0 and ($1) respectively	-1	3
Unrealized losses on the effective portion of designated hedges, net of tax benefit of $2	-3	0
Foreign currency translation adjustments	37	-114
Total other comprehensive income (loss)	36	-112
Comprehensive income	$106	$192

Consolidated_Statement_of_Comp1

Consolidated Statement of Comprehensive Income (Parentheticals) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Unrealized gains (losses) on securities, income tax (expense) benefit	$0	$0
Unfunded pension (losses) gains, income tax (expense) benefit	0	-1
Unrealized gains on the effective portion of designated hedges	$2	$0

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$1,381	$1,339
Marketable securities	2,666	2,641
Accounts receivable, less allowance of $68 ($72 in 2013)	1,430	1,518
Inventories	'	'
Materials and supplies	231	227
Work in process	96	85
Finished goods	1,171	1,110
Total inventories	1,498	1,422
Deferred income taxes	918	880
Prepaid expenses and other current assets	553	535
Total current assets	8,446	8,335
Property, plant and equipment	'	'
Land, buildings and improvements	692	686
Machinery and equipment	1,892	1,811
Total property, plant and equipment	2,584	2,497
Less allowance for depreciation	1,467	1,416
Net property, plant and equipment	1,117	1,081
Other assets	'	'
Goodwill	3,997	3,844
Other intangibles, net	2,085	1,989
Other	514	494
Total assets	16,159	15,743
Current liabilities	'	'
Accounts payable	350	314
Accrued compensation	333	535
Income taxes	118	131
Dividend payable	116	115
Accrued expenses and other liabilities	1,821	1,537
Current maturities of debt	820	25
Total current liabilities	3,558	2,657
Long-term debt, excluding current maturities	2,244	2,739
Other liabilities	1,294	1,300
Shareholders' equity	'	'
Common stock, $0.10 par value:	38	38
Additional paid-in capital	1,186	1,160
Retained earnings	7,571	7,617
Accumulated other comprehensive income	268	232
Total shareholders' equity	9,063	9,047
Total liabilities & shareholders' equity	$16,159	$15,743

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, except Share data, unless otherwise specified
Accounts receivable, allowance	$68	$72
Common stock, par value	$0.10	$0.10
Common stock, authorized	1,000	1,000
Common stock, outstanding	378	378

Consolidated_Statement_Of_Shar

Consolidated Statement Of Shareholders' Equity (USD $)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income
In Millions
Balances at December 31, 2013 at Dec. 31, 2013	$9,047	$38	$1,160	$7,617	$232
Net earnings	70	'	'	70	'
Other comprehensive income	36	'	'	'	36
Issuance of 1.4 million shares of common stock under stock option and benefit plans, including $2 excess income tax benefit	5	'	5	'	'
Share-based compensation	21	'	21	'	'
Cash dividends declared of $0.305 per share of common stock	-116	'	'	-116	'
Balances at March 31, 2014 at Mar. 31, 2014	$9,063	$38	$1,186	$7,571	$268

Consolidated_Statement_Of_Shar1

Consolidated Statement Of Shareholders' Equity (Parenthetical) (USD $)	3 Months Ended	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014
Issuance of common stock under stock option and benefit plans, shares	1.4	5.9
Issuance of common stock under stock option and benefit plans, excess income tax benefit	$2	$5
Repurchase and retirement of common stock, shares	0	0
Cash dividends declared, per share of common stock	$0.31	$0.27

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net earnings	$70	$304
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'
Depreciation	46	38
Intangible asset amortization	45	32
Share-based compensation	21	20
Restructuring charges	5	14
Sale of inventory stepped up to fair value at acquisition	5	'
Changes in operating assets and liabilities, net of effects of acquisitions:	'	'
Accounts receivable	93	7
Inventories	-61	-38
Accounts payable	30	-9
Accrued expenses and other liabilities	89	-112
Income taxes	-56	-9
Other	-81	-11
Net cash provided by operating activities	206	236
Investing activities	'	'
Acquisitions, net of cash acquired	-272	-600
Purchases of marketable securities	-1,017	-773
Proceeds from sales of marketable securities	1,008	1,062
Purchases of property, plant and equipment	-70	-49
Net cash used in investing activities	-351	-360
Financing activities	'	'
Proceeds from borrowings	344	1,060
Payments on borrowings	-55	-51
Dividends paid	-115	-101
Repurchase and retirement of common stock	'	-250
Other	12	-7
Net cash provided by financing activities	186	651
Effect of exchange rate changes on cash and cash equivalents	1	-9
Change in cash and cash equivalents	$42	$518

Basis_Of_Presentation

Basis Of Presentation	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis Of Presentation	'
	BASIS OF PRESENTATION
	General Information
	These statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2013. Management believes that the accompanying unaudited Consolidated Financial Statements include all adjustments, including normal recurring items, considered necessary for a fair presentation of the interim periods. The results of operations for the three-month period ended March 31, 2014 are not necessarily indicative of annual results.
	Certain prior year amounts in our Segment Information in Note 11 have been reclassified to conform with the presentation used in 2014.

Subsequent_Event_Subsequent_Ev

Subsequent Event Subsequent Event Narrative (Notes)	3 Months Ended
	Mar. 31, 2014
Subsequent Event [Line Items]	'
Subsequent Events [Text Block]	'
	SUBSEQUENT EVENT
	As further described in Note 7, on April 15, 2014 we completed the acquisition of Berchtold Holding, AG, a privately-held provider of surgical infrastructure equipment with operating facilities in Germany and the United States, for an aggregate purchase price of approximately $172.

Reclassification_Adjustments_O

Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) (Notes)	3 Months Ended
	Mar. 31, 2014
Reclassification Adjustments Out of Accumulated Other Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME (AOCI)
	Changes in and reclassifications out of AOCI, net of tax, for the three-month periods ended March 31, 2014 and 2013 were as follows:
		Marketable Securities Unrealized Gain (Loss)								Defined Benefit Pension Plans							Unrecognized Gain (Loss) on Hedge					Foreign Currency Translation					Total AOCI
		2014				2013				2014				2013			2014			2013		2014		2013			2014			2013
	Beginning balance	$	—			$	4			$	(81	)		$	(101	)	$	7		$	—	$	306	$	226		$	232		$	129
	Other comprehensive income (OCI)	5				2				(3		)		1			(2		)	—		37		(114		)	37			(111		)
	Reclassifications out of AOCI	(2		)		(3		)		2				2			(1		)	—		—		—			(1		)	(1		)
	Net current-period OCI	3				(1		)		(1		)		3			(3		)	—		37		(114		)	36			(112		)
	Balance at March 31	$	3			$	3			$	(82	)		$	(98	)	$	4		$	—	$	343	$	112		$	268		$	17
	The following items were reclassified out of AOCI into earnings for the three-month periods ended March 31, 2014 and 2013:
			2014						2013
	Detail of AOCI Components		Amount Reclassified				Reclassified To		Amount Reclassified				Reclassified To
	Unrealized gains on available-for-sale marketable securities		$	(2	)		Other (income) expense		$	(5	)		Other (income) expense
			—				Income tax expense		2				Income tax expense
			$	(2	)		Net of tax		$	(3	)		Net of tax
	Amortization of defined benefit pension plan actuarial losses		$	2			Cost of sales		$	2			Cost of sales
			—				Income tax benefit		—				Income tax benefit
			$	2			Net of tax		$	2			Net of tax
	Unrealized losses on designated hedges		$	(2	)		Cost of sales		$	—			Cost of sales
			—				Other (income) expense		—				Other (income) expense
			1				Income tax expense		—				Income tax expense
			$	(1	)		Net of tax		$	—			Net of tax

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	FAIR VALUE MEASUREMENTS
	Our valuation of our assets and liabilities measured at fair value is:
		Total							Level 1				Level 2						Level 3
		March			31-Dec				March		31-Dec		March			31-Dec			March		31-Dec
		2014			2013				2014		2013		2014			2013			2014		2013
	Assets:
	Cash and cash equivalents	$	1,381		$	1,339			$	1,381	$	1,339	$	—		$	—		$	—	$	—
	Available-for-sale marketable securities
	Corporate and asset-backed debt securities	1,172			1,177				—		—		1,172			1,177			—		—
	Foreign government debt securities	828			845				—		—		828			845			—		—
	United States agency debt securities	124			211				—		—		124			211			—		—
	United States treasury debt securities	487			350				—		—		487			350			—		—
	Certificates of deposit	51			53				—		—		51			53			—		—
	Other	4			5				—		—		4			5			—		—
	Total available-for-sale marketable securities	2,666			2,641				—		—		2,666			2,641			—		—
	Trading marketable securities	74			72				74		72		—			—			—		—
	Foreign currency exchange forward contracts	17			25				—		—		17			25			—		—
		$	4,138		$	4,077			$	1,455	$	1,411	$	2,683		$	2,666		$	—	$	—
	Liabilities:
	Deferred compensation arrangements	$	74		$	72			$	74	$	72	$	—		$	—		$	—	$	—
	Contingent consideration	47			59				—		—		—			—			47		59
	Foreign currency exchange forward contracts	6			2				—		—		6			2			—		—
		$	127		$	133			$	74	$	72	$	6		$	2		$	47	$	59
	We calculate the fair value of our Level 1 and Level 2 instruments based on the exchange traded price of similar or identical instruments, where available, or based on other observable inputs taking into account our credit risk and that of our counterparties. The fair value of our Level 3 liabilities represent milestone payments for acquisitions and is calculated as the net present value of expected cash flows (using a discounted cash flow technique) based on externally provided or obtained inputs, including our probability assessments of the occurrence of triggering events, appropriately discounted considering the uncertainties associated with the obligation. We remeasure this liability each reporting period and record the changes in the fair value in general and administrative expense (for probability of occurrence) and other income (expense) (for changes in time value of money) in earnings. During the period we evaluated but did not change our unobservable input assumptions and fair value techniques used in measuring the fair value of any financial assets or liabilities from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013. There were no significant transfers into or out of any levels that occurred between December 31, 2013 and March 31, 2014.
	Rollforward of liabilities measured at fair value using unobservable inputs (Level 3):
		March				December
		2014				2013
	Balance at the beginning of the period	$	59			$	103
	Losses included in earnings	—				(5		)
	Settlements	(12		)		(39		)
	Balance at the end of the period	$	47			$	59
	Summary of marketable securities:
		Amortized Cost							Gross Unrealized Gains				Gross Unrealized Losses						Estimated Fair Value
		March			December				March		December		March			December			March		December
		2014			2013				2014		2013		2014			2013			2014		2013
	Available-for-sale marketable securities:
	Corporate and asset-backed debt securities	$	1,171		$	1,177			$	2	$	1	$	(1	)	$	(1	)	$	1,172	$	1,177
	Foreign government debt securities	826			846				2		—		—			(1		)	828		845
	United States agency debt securities	124			211				—		—		—			—			124		211
	United States treasury debt securities	487			350				—		—		—			—			487		350
	Certificates of deposit	51			53				—		—		—			—			51		53
	Other	4			5				—		—		—			—			4		5
	Total available-for-sale marketable securities	$	2,663		$	2,642			$	4	$	1	$	(1	)	$	(2	)	2,666		2,641
	Trading marketable securities																		74		72
	Total marketable securities																		$	2,740	$	2,713
	Reported as:
	Current assets-marketable securities																		$	2,666	$	2,641
	Noncurrent assets-other																		74		72
																			$	2,740	$	2,713
	The unrealized losses on available-for-sale marketable securities at March 31, 2014 were primarily caused by increases in yields as a result of the rise in government benchmark rates. Less than 1% of our investments in available-for-sale securities had a credit quality rating of less than A2 (Moody's), A (Standard & Poors) and A (Fitch). We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity; accordingly, we do not consider these investments to be other-than-temporarily impaired at March 31, 2014.
	The cost and estimated fair value of available-for-sale marketable securities at March 31, 2014 by contractual maturity are:
			Cost				Estimated
							Fair Value
	Due in one year or less		$	522			$	521
	Due after one year through three years		1,905				1,908
	Due after three years		236				237
			$	2,663			$	2,666
	The gross unrealized losses and fair value of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position at March 31, 2014 are:
		Corporate and Asset-Backed Debt Securities							Foreign Government Debt Securities				United States Agency Debt Securities						Other				Total
		Less Than 12 Months			Total				Less Than 12 Months		Total		Less Than 12 Months			Total			Less Than 12 Months		Total		Less Than 12 Months			Total
	Number of investments	170			173				86		93		46			46			114		115		416			427
	Fair value	$	389		$	396			$	490	$	576	$	228		$	228		$	15	$	15	$	1,122		$	1,215
	Unrealized losses	$	(1	)	$	(1	)		$	—	$	—	$	—		$	—		$	—	$	—	$	(1	)	$	(1	)
Upon the sale of a security classified as available-for-sale, the security’s specific unrealized gain (loss) is reclassified out of AOCI into earnings based on the specific identification method. Interest and marketable securities income was $6 and $5 for the three months ended March 31, 2014 and 2013, respectively, and is included in other income (expense).

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Strategies	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments And Hedging Strategies	'
	NOTE 5 - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
	We use operational and economic hedges as well as foreign currency exchange forward contracts to manage the impact of currency exchange on earnings and cash flow. During the period we did not change our hedging strategies or objectives from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013. The gross notional and gross fair value amounts of foreign exchange forward contract derivatives designated and non-designated as hedging instruments are:
		31-Mar-14															31-Dec-13
					Fair Value - Balance Sheet Location														Fair Value - Balance Sheet Location
		Gross Notional			Other Current Assets			Other Assets – Noncurrent			Other Current Liabilities			Other Liabilities – Noncurrent			Gross Notional		Other Current Assets		Other Assets – Noncurrent		Other Current Liabilities		Other Liabilities – Noncurrent
	Designated	$	315		$	5		$	1		$	2		$	1		$	344	$	11	$	1	$	1	$	—
	Non-designated	2,170			10			1			3			—			2,000		10		3		1		—
		$	2,485		$	15		$	2		$	5		$	1		$	2,344	$	21	$	4	$	2	$	—
	We are exposed to credit loss in the event of nonperformance by counterparties on our outstanding forward currency exchange contracts but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of the forward currency exchange contracts at March 31, 2014 and December 31, 2013 was 546 days for each period.
	The aggregate currency exchange rate gains (losses) for the three months ended March 31, 2014 was ($4), comprised of gains of $2 recorded in cost of goods sold and losses of ($6) recorded in other (income) expense. No aggregate gain (loss) was recorded for the three months ended March 31, 2013. These total gains (losses) represent the net impact to the consolidated statements of earnings for both designated and non-designated derivative instruments.
	The amount and location of gains in the consolidated statements of earnings and amounts recorded in AOCI related to the foreign exchange contract derivative instruments designated as hedges for the three months ended March 31 were:
	Reported as a component of AOCI (net of tax effective portion)						Reclassified from AOCI into income (pre-tax effective portion)						Recognized in other income (expense) (pre-tax ineffective portion and amount excluded from effectiveness testing)
	2014			2013			2014			2013			2014			2013
	$	5		$	—		$	2		$	—		$	—		$	—
	At March 31, 2014 and December 31, 2013, deferred pretax gains on derivatives designated as hedges of $7 and $12, which are recorded in AOCI, are expected to be reclassified to current earnings during the next twelve months. This reclassification is primarily due to the sale of inventory that includes previously hedged purchases.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor and intellectual property, and other matters. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages, as well as other compensatory and equitable relief, that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management has sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, for the resolution of these legal matters is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those projected by management, additional expense may be incurred, which could unfavorably affect future operating results. We are currently self-insured for product liability-related claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.
	In 2010 we received a subpoena from the United States Department of Justice (DOJ) related to the sales and marketing of the OtisKnee device.  The subpoena concerns allegations of violations of federal laws related to sales of a device not cleared by the United States Food and Drug Administration (FDA).  We continue to discuss the settlement of this matter with the DOJ, but there can be no assurance that we will reach a consensual resolution rather than seeking a resolution through the courts. We have recorded charges totaling $80 related to this matter.
	In June 2012 we voluntarily recalled our Rejuvenate and ABG II modular-neck hip stems and terminated global distribution of these hip products. We notified healthcare professionals and regulatory bodies of this recall, which was taken due to potential risks associated with fretting and/or corrosion that may lead to adverse local tissue reactions. Product liability lawsuits relating to this voluntary recall have been filed against us. As previously announced, we intend to reimburse implanted patients for reasonable and customary costs of testing and treatment services, including any necessary revision surgeries. We continue to work with the medical community to evaluate the data and further understand this matter. The ultimate total cost with respect to this matter will depend on many factors that are difficult to predict and may vary materially based on the number of and actual costs of patients seeking testing and treatment services, the number of and actual costs of patients requiring revision surgeries, the number of and actual costs to settle lawsuits filed against us, and the amount of third-party insurance recoveries.  Based on the information that has been received, the actuarially determined range of probable loss to resolve this matter is estimated to be approximately $1,130 to $1,580 before third-party insurance recoveries.  In the three months ended March 31, 2014, we recorded charges to earnings of $340 representing the excess of the $1,130 minimum of the range over the previously recorded reserves. No contingent gain for third-party insurance recoveries was recorded as of March 31, 2014. As noted above, the final outcome of this matter is dependent on many variables that are difficult to predict.  The ultimate cost to entirely resolve this matter may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.
	In 2010 we filed a lawsuit in federal court against Zimmer Holdings, Inc. (Zimmer), alleging that a Zimmer product infringed three of our patents. In rulings issued in August and September 2013, the trial judge upheld the February 2013 jury verdict in our favor, issued a permanent injunction barring Zimmer from making or selling infringing products, and ordered Zimmer to pay us at least $228. Zimmer is appealing this ruling and the ultimate resolution of this matter may differ materially. Accordingly, we have not recorded a contingent gain related to this matter.
	For each of the following legal matters the final outcome is dependent on many variables and cannot be predicted. Accordingly, it is not possible at this time for us to estimate any material loss or range of losses. However, the ultimate cost to resolve these matters could have a material adverse effect on our financial position, results of operations and cash flows.
	In April 2011 lawsuits brought by Hill-Rom Company, Inc. and affiliated entities (Hill-Rom) against us were filed in the United States District Court for the Western District of Wisconsin and the United States District Court for the Southern District of Indiana.  The Wisconsin lawsuit was subsequently transferred to the United States District Court in Indiana. The suits allege infringement under United States patent laws with respect to certain patient handling equipment we manufactured and sold and seek damages and permanent injunctions. We have entered into an agreement settling the first lawsuit, with terms as previously disclosed. The second lawsuit involves nine patents related to electrical network communications for hospital beds. The case has been stayed with respect to six of the patents that are currently under reexamination by the United States Patent Office. With respect to the three remaining patents, Hill-Rom is appealing the trial court's grant of summary judgment in our favor and the ultimate resolution of this particular part of the suit may differ. The ultimate resolution of the entire second suit may have no relation to the resolution of the first suit and cannot be predicted; however, the result could have a material adverse effect on our financial position, results of operations and cash flows.
	In 2010 we received a subpoena from the DOJ related to sales and marketing and regulatory matters related to the Stryker PainPump. We have received requests for certain documents in connection with this investigation. The investigation is ongoing and we are fully cooperating with the DOJ regarding this matter.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	ACQUISITIONS
	In March 2014 we completed our acquisition of Patient Safety Technologies, Inc. (PST) for an aggregate purchase price of $120. PST conducts its business through its wholly owned subsidiary, SurgiCount Medical, Inc. PST’s proprietary Safety-Sponge® System and SurgiCount 360™ compliance software help prevent Retained Foreign Objects in the operating room. The acquisition of PST is expected to enhance our product offerings within our MedSurg segment. Intangible assets acquired with PST will be amortized over a weighted-average life of 14 years.
	Other business acquisitions completed in the three-month period in 2014 include the previously announced acquisition of Pivot Medical, Inc. (Pivot). The acquired net assets of these acquisitions appear in the "Other" column in the table below.
	In February 2014 we announced our intent to acquire Berchtold Holding, AG (Berchtold); on April 15, 2014 the acquisition closed for an aggregate purchase price of approximately $172. Berchtold, a privately held business with operating facilities in Germany and the United States, sells surgical infrastructure equipment including surgical tables, equipment booms and surgical lighting systems. The acquisition of Berchtold is expected to enhance our product offerings within our MedSurg segment.
	In December 2013 we acquired MAKO Surgical Corp. (MAKO) for an aggregate purchase price of $1,679. The acquisition of MAKO, combined with our strong history in joint reconstruction, capital equipment (operating room integration and surgical navigation) and surgical instruments, will help further advance the growth of robotic arm assisted surgery. Our combined expertise offers the potential to simplify joint reconstruction procedures, reduce variability and enhance the surgeon and patient experience. The acquisition of MAKO enhances our product offerings within our Reconstructive segment. Intangible assets acquired with MAKO will be amortized over a weighted-average life of 9 years, except for the trade name that is deemed to have an indefinite life. In-process research and development (IPRD) is considered to be an indefinite-lived intangible asset until such time as the research is completed (at which time it becomes a determinable-lived intangible asset) or determined to have no future use (at which time it is impaired).
	The purchase price allocations for MAKO, PST and other smaller acquisitions are based upon preliminary valuations, and our estimates and assumptions are subject to change within the measurement period as the valuations are finalized. Management is currently in the process of verifying data and finalizing information related to the MAKO valuation and all acquisitions completed in 2014 to finalize the recording of identifiable intangible assets, deferred income taxes and the corresponding effect on the value of goodwill.
	In March 2013 we acquired Trauson Holdings Company Limited (Trauson) for an aggregate purchase price of $751. The acquisition of Trauson enhances our product offerings, primarily within our Reconstructive segment, broadens our presence in China and enables us to expand into the fast growing value segment of the emerging markets. Intangible assets acquired with Trauson will be amortized over a weighted-average life of 15 years, except for the trade name that is deemed to have an indefinite life. IPRD is considered to be an indefinite-lived intangible asset until the research is completed (at which time it becomes a determinable-lived intangible asset) or it is determined to have no future use (at which time it is impaired). The measurement period for the Trauson acquisition was completed in 2013.
	The allocation of the purchase prices of each acquisition to the acquired net assets is as follows:
		2014			2014			2013			2013
		PST			Other			MAKO			Trauson
	Purchase price paid	$	120		$	148		$	1,679		$	751
	Tangible assets acquired:
	Inventory	7			5			50			43
	Other assets	19			25			174			163
	Liabilities	(33		)	(32		)	(277		)	(87		)
	Identifiable intangible assets:
	Customer relationship	33			4			91			112
	Trade name	—			—			24			34
	Developed technology & patents	26			70			231			31
	IPRD	—			2			169			5
	Goodwill	68			74			1,217			450
		$	120		$	148		$	1,679		$	751

LongTerm_Debt_and_Credit_Facil

Long-Term Debt and Credit Facilities	3 Months Ended
	Mar. 31, 2014
Long-term Debt, Unclassified [Abstract]	'
Long-Term Debt And Credit Facilities	'
	LONG-TERM DEBT AND CREDIT FACILITIES
	Our debt is summarized as follows:
			31-Mar			31-Dec
			2014			2013
	Senior unsecured notes:
	Rate	Due
	3.00%	15-Jan-15	$	500		$	500
	2.00%	30-Sep-16	749			749
	1.30%	1-Apr-18	598			598
	4.38%	15-Jan-20	498			498
	4.10%	1-Apr-43	395			394
	Commercial paper		300			—
	Other		24			25
	Total debt		3,064			2,764
	Less current maturities		(820		)	(25		)
		Total long-term debt	$	2,244		$	2,739
	During the three months ended March 31, 2014, we issued commercial paper under the commercial paper program we established in July 2011. The program allows us to have a maximum of $500 in commercial paper outstanding, with maturities up to 397 days from the date of issuance. As of March 31, 2014, outstanding commercial paper totaled $300, the weighted average original maturity of the commercial paper outstanding was approximately 13 days and the weighted average interest rate was 0.3%.
	In March 2013 we completed a public offering of $600 in 1.30% Notes due April 1, 2018, net of an offering discount of $3 (2018 Notes), and $400 in 4.10% Notes due April 1, 2043, net of an offering discount of $6 (2043 Notes and, together with the 2018 Notes, the Notes). Interest on the Notes is payable on April 1 and October 1 of each year, commencing on October 1, 2013. Unless previously redeemed, the 2018 Notes will mature on April 1, 2018 and the 2043 Notes will mature on April 1, 2043.
	Certain of our credit facilities require us to comply with certain financial and other covenants. We were in compliance with all covenants at March 31, 2014. We have lines of credit, issued by various financial institutions, available to fund our day-to-day operating needs. At March 31, 2014, we had $762 of borrowing capacity available under all of our existing credit facilities. The weighted average interest rate, excluding required fees, for all borrowings was 2.7% at March 31, 2014.
	At December 31, 2013, the total unamortized debt issuance costs incurred in connection with our outstanding notes were $15. The fair value of long-term debt (including current maturities) at March 31, 2014 and December 31, 2013 was $2,792 and $2,790, respectively, based on the quoted interest rates for similar types and amounts of borrowing agreements.

Capital_Stock

Capital Stock	3 Months Ended
	Mar. 31, 2014
Capital Stock Disclosures [Abstract]	'
Capital Stock	'
	CAPITAL STOCK
	In February 2014 we declared a quarterly dividend of $0.305 per share, payable April 30, 2014 to shareholders of record at the close of business on March 31, 2014.
	We did not repurchase any shares during the three months ended March 31, 2014. At March 31, 2014, the maximum dollar value of shares that may be purchased under authorized repurchase programs was $683.

Restructuring_Charges

Restructuring Charges	3 Months Ended
	Mar. 31, 2014
Restructuring Charges [Abstract]	'
Restructuring Charges	'
	RESTRUCTURING CHARGES
	In recent years, we have incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization. The costs incurred under the ongoing program have generally ranged from $50 to $75 annually. The productivity and cost savings plan was designed to accelerate cost reductions by streamlining management decision making, manufacturing and other work processes to help fund our growth strategy.
	A rollforward of our restructuring liability balance for the three months ended March 31, 2014 is as follows:
		Total			Agent Conversions			Severance and Related Costs			Contractual Obligations and Other
	January 1 Balance	$	20		$	2		$	10		$	8
	Charges to earnings	5			—			3			2
	Cash paid	(8		)	(1		)	(4		)	(3		)
	Other adjustments	(1		)	—			(1		)	—
	March 31 Balance	$	16		$	1		$	8		$	7

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	SEGMENT INFORMATION
	Net sales and net earnings by business segment for the three months ended March 31, 2014 and 2013 are as follows:
		Reconstructive				MedSurg				Neurotechnology and Spine				Total
		2014		2013		2014		2013		2014		2013		2014			2013
	Net sales	$	999	$	956	$	886	$	837	$	420	$	397	$	2,305		$	2,190
	Segment net earnings	249		234		145		161		86		78		$	480		$	473
	Less: other (net of income taxes)
	Other													(76		)	(56		)
	Acquisition and integration related charges													(13		)	(17		)
	Intangible Amortization													(31		)	(23		)
	Restructuring and related charges													(10		)	(11		)
	Recall charges													(272		)	(32		)
	Regulatory matter charges													—			(30		)
	Tax matters													(8		)	—
	Net earnings													$	70		$	304
	Other than assets associated with the acquisitions that are discussed in greater detail in Note 7, there were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for the year ended December 31, 2013.

Reclassification_Adjustments_O1

Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) (Tables)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'
		Marketable Securities Unrealized Gain (Loss)								Defined Benefit Pension Plans							Unrecognized Gain (Loss) on Hedge					Foreign Currency Translation					Total AOCI
		2014				2013				2014				2013			2014			2013		2014		2013			2014			2013
	Beginning balance	$	—			$	4			$	(81	)		$	(101	)	$	7		$	—	$	306	$	226		$	232		$	129
	Other comprehensive income (OCI)	5				2				(3		)		1			(2		)	—		37		(114		)	37			(111		)
	Reclassifications out of AOCI	(2		)		(3		)		2				2			(1		)	—		—		—			(1		)	(1		)
	Net current-period OCI	3				(1		)		(1		)		3			(3		)	—		37		(114		)	36			(112		)
	Balance at March 31	$	3			$	3			$	(82	)		$	(98	)	$	4		$	—	$	343	$	112		$	268		$	17
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
			2014						2013
	Detail of AOCI Components		Amount Reclassified				Reclassified To		Amount Reclassified				Reclassified To
	Unrealized gains on available-for-sale marketable securities		$	(2	)		Other (income) expense		$	(5	)		Other (income) expense
			—				Income tax expense		2				Income tax expense
			$	(2	)		Net of tax		$	(3	)		Net of tax
	Amortization of defined benefit pension plan actuarial losses		$	2			Cost of sales		$	2			Cost of sales
			—				Income tax benefit		—				Income tax benefit
			$	2			Net of tax		$	2			Net of tax
	Unrealized losses on designated hedges		$	(2	)		Cost of sales		$	—			Cost of sales
			—				Other (income) expense		—				Other (income) expense
			1				Income tax expense		—				Income tax expense
			$	(1	)		Net of tax		$	—			Net of tax

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets And Liabilities Measured On Recurring Basis	'
		Total							Level 1				Level 2						Level 3
		March			31-Dec				March		31-Dec		March			31-Dec			March		31-Dec
		2014			2013				2014		2013		2014			2013			2014		2013
	Assets:
	Cash and cash equivalents	$	1,381		$	1,339			$	1,381	$	1,339	$	—		$	—		$	—	$	—
	Available-for-sale marketable securities
	Corporate and asset-backed debt securities	1,172			1,177				—		—		1,172			1,177			—		—
	Foreign government debt securities	828			845				—		—		828			845			—		—
	United States agency debt securities	124			211				—		—		124			211			—		—
	United States treasury debt securities	487			350				—		—		487			350			—		—
	Certificates of deposit	51			53				—		—		51			53			—		—
	Other	4			5				—		—		4			5			—		—
	Total available-for-sale marketable securities	2,666			2,641				—		—		2,666			2,641			—		—
	Trading marketable securities	74			72				74		72		—			—			—		—
	Foreign currency exchange forward contracts	17			25				—		—		17			25			—		—
		$	4,138		$	4,077			$	1,455	$	1,411	$	2,683		$	2,666		$	—	$	—
	Liabilities:
	Deferred compensation arrangements	$	74		$	72			$	74	$	72	$	—		$	—		$	—	$	—
	Contingent consideration	47			59				—		—		—			—			47		59
	Foreign currency exchange forward contracts	6			2				—		—		6			2			—		—
		$	127		$	133			$	74	$	72	$	6		$	2		$	47	$	59
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
		March				December
		2014				2013
	Balance at the beginning of the period	$	59			$	103
	Losses included in earnings	—				(5		)
	Settlements	(12		)		(39		)
	Balance at the end of the period	$	47			$	59
Summary Of Marketable Securities	'
	Summary of marketable securities:
		Amortized Cost							Gross Unrealized Gains				Gross Unrealized Losses						Estimated Fair Value
		March			December				March		December		March			December			March		December
		2014			2013				2014		2013		2014			2013			2014		2013
	Available-for-sale marketable securities:
	Corporate and asset-backed debt securities	$	1,171		$	1,177			$	2	$	1	$	(1	)	$	(1	)	$	1,172	$	1,177
	Foreign government debt securities	826			846				2		—		—			(1		)	828		845
	United States agency debt securities	124			211				—		—		—			—			124		211
	United States treasury debt securities	487			350				—		—		—			—			487		350
	Certificates of deposit	51			53				—		—		—			—			51		53
	Other	4			5				—		—		—			—			4		5
	Total available-for-sale marketable securities	$	2,663		$	2,642			$	4	$	1	$	(1	)	$	(2	)	2,666		2,641
	Trading marketable securities																		74		72
	Total marketable securities																		$	2,740	$	2,713
	Reported as:
	Current assets-marketable securities																		$	2,666	$	2,641
	Noncurrent assets-other																		74		72
																			$	2,740	$	2,713
Investments Classified By Contractual Maturity Date	'
			Cost				Estimated
							Fair Value
	Due in one year or less		$	522			$	521
	Due after one year through three years		1,905				1,908
	Due after three years		236				237
			$	2,663			$	2,666
Investments In A Continuous Unrealized Loss Position	'
		Corporate and Asset-Backed Debt Securities							Foreign Government Debt Securities				United States Agency Debt Securities						Other				Total
		Less Than 12 Months			Total				Less Than 12 Months		Total		Less Than 12 Months			Total			Less Than 12 Months		Total		Less Than 12 Months			Total
	Number of investments	170			173				86		93		46			46			114		115		416			427
	Fair value	$	389		$	396			$	490	$	576	$	228		$	228		$	15	$	15	$	1,122		$	1,215
	Unrealized losses	$	(1	)	$	(1	)		$	—	$	—	$	—		$	—		$	—	$	—	$	(1	)	$	(1	)

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Strategies (Tables)	3 Months Ended
	Mar. 31, 2014
Derivatives, Fair Value [Line Items]	'
Derivative Instruments, Gain (Loss) [Table Text Block]	'
	Reported as a component of AOCI (net of tax effective portion)						Reclassified from AOCI into income (pre-tax effective portion)						Recognized in other income (expense) (pre-tax ineffective portion and amount excluded from effectiveness testing)
	2014			2013			2014			2013			2014			2013
	$	5		$	—		$	2		$	—		$	—		$	—
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	'
		31-Mar-14															31-Dec-13
					Fair Value - Balance Sheet Location														Fair Value - Balance Sheet Location
		Gross Notional			Other Current Assets			Other Assets – Noncurrent			Other Current Liabilities			Other Liabilities – Noncurrent			Gross Notional		Other Current Assets		Other Assets – Noncurrent		Other Current Liabilities		Other Liabilities – Noncurrent
	Designated	$	315		$	5		$	1		$	2		$	1		$	344	$	11	$	1	$	1	$	—
	Non-designated	2,170			10			1			3			—			2,000		10		3		1		—
		$	2,485		$	15		$	2		$	5		$	1		$	2,344	$	21	$	4	$	2	$	—

Acquisitions_Acquisitions_Tabl

Acquisitions Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Schedule of Purchase Price Allocation [Table Text Block]	'
	llows:
		2014			2014			2013			2013
		PST			Other			MAKO			Trauson
	Purchase price paid	$	120		$	148		$	1,679		$	751
	Tangible assets acquired:
	Inventory	7			5			50			43
	Other assets	19			25			174			163
	Liabilities	(33		)	(32		)	(277		)	(87		)
	Identifiable intangible assets:
	Customer relationship	33			4			91			112
	Trade name	—			—			24			34
	Developed technology & patents	26			70			231			31
	IPRD	—			2			169			5
	Goodwill	68			74			1,217			450
		$	120		$	148		$	1,679		$	751

LongTerm_Debt_and_Credit_Facil1

Long-Term Debt and Credit Facilities (Tables)	3 Months Ended
	Mar. 31, 2014
Long-term Debt, Unclassified [Abstract]	'
Maturities Of Long-Term Debt Disclosures	'
			31-Mar			31-Dec
			2014			2013
	Senior unsecured notes:
	Rate	Due
	3.00%	15-Jan-15	$	500		$	500
	2.00%	30-Sep-16	749			749
	1.30%	1-Apr-18	598			598
	4.38%	15-Jan-20	498			498
	4.10%	1-Apr-43	395			394
	Commercial paper		300			—
	Other		24			25
	Total debt		3,064			2,764
	Less current maturities		(820		)	(25		)
		Total long-term debt	$	2,244		$	2,739

Restructuring_Charges_Tables

Restructuring Charges (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring Charges [Abstract]	'
Restructuring Charges	'
		Total			Agent Conversions			Severance and Related Costs			Contractual Obligations and Other
	January 1 Balance	$	20		$	2		$	10		$	8
	Charges to earnings	5			—			3			2
	Cash paid	(8		)	(1		)	(4		)	(3		)
	Other adjustments	(1		)	—			(1		)	—
	March 31 Balance	$	16		$	1		$	8		$	7

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Sales and Other Financial Information by Business Segment	'
		Reconstructive				MedSurg				Neurotechnology and Spine				Total
		2014		2013		2014		2013		2014		2013		2014			2013
	Net sales	$	999	$	956	$	886	$	837	$	420	$	397	$	2,305		$	2,190
	Segment net earnings	249		234		145		161		86		78		$	480		$	473
	Less: other (net of income taxes)
	Other													(76		)	(56		)
	Acquisition and integration related charges													(13		)	(17		)
	Intangible Amortization													(31		)	(23		)
	Restructuring and related charges													(10		)	(11		)
	Recall charges													(272		)	(32		)
	Regulatory matter charges													—			(30		)
	Tax matters													(8		)	—
	Net earnings													$	70		$	304

Subsequent_Event_Details

Subsequent Event (Details) (Other, USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Other	'
Subsequent Event [Line Items]	'
Purchase price paid	$172

Reclassification_Adjustments_O2

Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) Changes in AOCI balances net of tax (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Beginning balance	$232	$129
Other comprehensive income (OCI)	37	-111
Reclassifications out of AOCI	-1	-1
Total other comprehensive income (loss)	36	-112
Balance at March 31	268	17
Marketable Securities Unrealized Gain (Loss)	'	'
Beginning balance	'	4
Other comprehensive income (OCI)	5	2
Reclassifications out of AOCI	-2	-3
Total other comprehensive income (loss)	3	-1
Balance at March 31	3	3
Defined Benefit Pension Plans	'	'
Beginning balance	-81	-101
Other comprehensive income (OCI)	-3	1
Reclassifications out of AOCI	2	2
Total other comprehensive income (loss)	-1	3
Balance at March 31	-82	-98
Unrecognized Gain (Loss) on Hedge	'	'
Beginning balance	7	0
Other comprehensive income (OCI)	-2	0
Reclassifications out of AOCI	-1	0
Total other comprehensive income (loss)	-3	0
Balance at March 31	4	0
Foreign Currency Translation	'	'
Beginning balance	306	226
Other comprehensive income (OCI)	37	-114
Reclassifications out of AOCI	0	0
Total other comprehensive income (loss)	37	-114
Balance at March 31	$343	$112

Reclassification_Adjustments_O3

Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income taxes	$37	$71
Net Income (Loss) Attributable to Parent	70	304
Reclassification out of Accumulated Other Comprehensive Income [Member] | Marketable Securities Unrealized Gain (Loss)	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax	-2	-5
Income taxes	0	2
Net Income (Loss) Attributable to Parent	-2	-3
Reclassification out of Accumulated Other Comprehensive Income [Member] | Defined Benefit Pension Plans	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax	2	2
Income taxes	0	0
Net Income (Loss) Attributable to Parent	2	2
Reclassification out of Accumulated Other Comprehensive Income [Member] | Unrecognized Gain (Loss) on Hedge	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax	0	0
Income taxes	1	0
Net Income (Loss) Attributable to Parent	-1	0
Cost of Sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Unrecognized Gain (Loss) on Hedge	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax	($2)	$0

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Interest and marketable securities income	$6	$0
Interest Income (Expense), Net	1	0
Marketable Securities, Gain (Loss)	$5	$5
Corporate and asset-backed debt securities | Standard & Poor's, A Rating [Member]	'	'
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2	1.00%	'
Corporate and asset-backed debt securities | Fitch, A Rating [Member]	'	'
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2	1.00%	'
Corporate and asset-backed debt securities | Moody's, A2 Rating [Member]	'	'
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2	1.00%	'

Fair_Value_Measurements_Valuat

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Assets:	'	'
Cash and cash equivalents	$1,381	$1,339
Foreign currency exchange forward contracts	17	25
Total	4,138	4,077
Liabilities:	'	'
Deferred compensation arrangements	74	72
Contingent consideration	47	59
Foreign currency exchange forward contracts	6	2
Total	127	133
Available-for-sale marketable securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	2,666	2,641
Available-for-sale marketable securities | Corporate and asset-backed debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	1,172	1,177
Available-for-sale marketable securities | Foreign government debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	828	845
Available-for-sale marketable securities | United States agency debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	124	211
Available-for-sale marketable securities | United States treasury debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	487	350
Available-for-sale marketable securities | Certificates of deposit	'	'
Assets:	'	'
Total available-for-sale marketable securities	51	53
Available-for-sale marketable securities | Other	'	'
Assets:	'	'
Total available-for-sale marketable securities	4	5
Trading marketable securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	74	72
Level 1	'	'
Assets:	'	'
Cash and cash equivalents	1,381	1,339
Total	1,455	1,411
Liabilities:	'	'
Deferred compensation arrangements	74	72
Total	74	72
Level 1 | Trading marketable securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	74	72
Level 2	'	'
Assets:	'	'
Foreign currency exchange forward contracts	17	25
Total	2,683	2,666
Liabilities:	'	'
Foreign currency exchange forward contracts	6	2
Total	6	2
Level 2 | Available-for-sale marketable securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	2,666	2,641
Level 2 | Available-for-sale marketable securities | Corporate and asset-backed debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	1,172	1,177
Level 2 | Available-for-sale marketable securities | Foreign government debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	828	845
Level 2 | Available-for-sale marketable securities | United States agency debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	124	211
Level 2 | Available-for-sale marketable securities | United States treasury debt securities	'	'
Assets:	'	'
Total available-for-sale marketable securities	487	350
Level 2 | Available-for-sale marketable securities | Certificates of deposit	'	'
Assets:	'	'
Total available-for-sale marketable securities	51	53
Level 2 | Available-for-sale marketable securities | Other	'	'
Assets:	'	'
Total available-for-sale marketable securities	4	5
Level 3	'	'
Liabilities:	'	'
Contingent consideration	47	59
Total	$47	$59

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets and Liabilities Measured At Fair Value On A Recurring Basis Using Unobservable Inputs (Level 3)) (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Document Fiscal Year Focus	'2014	'
Contingent consideration	'	'
Balance at the beginning of the period	$59	$103
Losses included in earnings	'	-5
Settlements	-12	-39
Balance at the end of the period	$47	$59

Fair_Value_Measurements_Market

Fair Value Measurements (Marketable Securities) (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Document Fiscal Year Focus	'2014	'	'
Estimated Fair Value	$2,740	'	$2,713
Available-for-sale marketable securities	'	'	'
Amortized Cost	2,663	'	2,642
Gross Unrealized Gains	4	1	'
Gross Unrealized Losses	-1	-2	'
Estimated Fair Value	2,666	'	2,641
Trading marketable securities	'	'	'
Estimated Fair Value	74	'	72
Available-for-sale marketable securities	'	'	'
Estimated Fair Value	2,666	'	2,641
Noncurrent assets-other	'	'	'
Estimated Fair Value	74	'	72
Corporate and asset-backed debt securities | Available-for-sale marketable securities	'	'	'
Amortized Cost	1,171	'	1,177
Gross Unrealized Gains	2	1	'
Gross Unrealized Losses	-1	-1	'
Estimated Fair Value	1,172	'	1,177
Foreign government debt securities | Available-for-sale marketable securities	'	'	'
Amortized Cost	826	'	846
Gross Unrealized Gains	2	'	'
Gross Unrealized Losses	'	-1	'
Estimated Fair Value	828	'	845
United States agency debt securities | Available-for-sale marketable securities	'	'	'
Amortized Cost	124	'	211
Estimated Fair Value	124	'	211
United States treasury debt securities | Available-for-sale marketable securities	'	'	'
Amortized Cost	487	'	350
Estimated Fair Value	487	'	350
Certificates of deposit | Available-for-sale marketable securities	'	'	'
Amortized Cost	51	'	53
Estimated Fair Value	51	'	53
Other | Available-for-sale marketable securities	'	'	'
Amortized Cost	4	'	5
Estimated Fair Value	$4	'	$5

Fair_Value_Measurements_Net_Ca

Fair Value Measurements (Net Carrying Value And Estimated Fair Value Of Available-For-Sale Marketable Securities) (Details) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Due in one year or less, Cost	$522
Due in one year or less, Estimated Fair Value	521
Due after one year through three years, Cost	1,905
Due after one year through three years, Estimated Fair Value	1,908
Due after three years, Cost	236
Due after three years, Estimated Fair Value	237
Fair value of available-for-sale marketable securities, Cost	2,663
Fair value of available-for-sale marketable securities, Estimated Fair Value	$2,666

Fair_Value_Measurements_Unreal

Fair Value Measurements (Unrealized Losses And Fair Value Of Investments With Unrealized Losses) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Less Than 12 Months - Number of Investments	416
Less Than 12 Months - Fair Value	$1,122
Less Than 12 Months - Unrealized Losses	1
Total - Number of Investments	427
Total - Fair Value	1,215
Total - Unrealized Losses	1
Corporate and asset-backed debt securities	'
Less Than 12 Months - Number of Investments	170
Less Than 12 Months - Fair Value	389
Less Than 12 Months - Unrealized Losses	1
Total - Number of Investments	173
Total - Fair Value	396
Total - Unrealized Losses	1
Foreign government debt securities	'
Less Than 12 Months - Number of Investments	86
Less Than 12 Months - Fair Value	490
Total - Number of Investments	93
Total - Fair Value	576
United States agency debt securities	'
Less Than 12 Months - Number of Investments	46
Less Than 12 Months - Fair Value	228
Total - Number of Investments	46
Total - Fair Value	228
Other	'
Less Than 12 Months - Number of Investments	114
Less Than 12 Months - Fair Value	15
Total - Number of Investments	115
Total - Fair Value	$15

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Strategies (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended	3 Months Ended		12 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Mar. 31, 2013
			Foreign Exchange Contract [Member]	Foreign Exchange Contract [Member]	Foreign Exchange Contract [Member]	Foreign Exchange Contract [Member]	Foreign Exchange Contract [Member]
				Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]	Cost of Sales [Member]	Other Expense [Member]
Foreign currency transaction losses	'	'	$0	'	'	$0	$0
Maximum Term (Days)	'546 days	'546 days	'	'	'	'	'
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months	'	'	'	$7	$12	'	'

Derivative_Instruments_and_Hed3

Derivative Instruments and Hedging Strategies (Forward Currency Exchange Contracts) (Details) (Foreign Exchange Contract [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Notional Amount	$2,485	'	$2,344
Designated as Hedging Instrument [Member]	'	'	'
Notional Amount	315	'	344
Derivative Instruments, Gain (Loss) Recognized in Accumulated OCI, Effective Portion, Net	5	0	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	2	0	'
Not Designated as Hedging Instrument [Member]	'	'	'
Notional Amount	2,170	'	2,000
Other Current Assets	'	'	'
Derivative Asset, Fair Value, Gross Asset	15	'	21
Other Current Assets | Designated as Hedging Instrument [Member]	'	'	'
Derivative Asset, Fair Value, Gross Asset	5	'	11
Other Current Assets | Not Designated as Hedging Instrument [Member]	'	'	'
Derivative Asset, Fair Value, Gross Asset	10	'	10
Other Assets b Noncurrent	'	'	'
Derivative Asset, Fair Value, Gross Asset	2	'	4
Other Assets b Noncurrent | Designated as Hedging Instrument [Member]	'	'	'
Derivative Asset, Fair Value, Gross Asset	1	'	1
Other Assets b Noncurrent | Not Designated as Hedging Instrument [Member]	'	'	'
Derivative Asset, Fair Value, Gross Asset	1	'	3
Other Current Liabilities	'	'	'
Derivative Liability, Fair Value, Gross Liability	5	'	2
Other Current Liabilities | Designated as Hedging Instrument [Member]	'	'	'
Derivative Liability, Fair Value, Gross Liability	2	'	1
Other Current Liabilities | Not Designated as Hedging Instrument [Member]	'	'	'
Derivative Liability, Fair Value, Gross Liability	3	'	1
Other Liabilities b Noncurrent	'	'	'
Derivative Liability, Fair Value, Gross Liability	1	'	0
Other Liabilities b Noncurrent | Designated as Hedging Instrument [Member]	'	'	'
Derivative Liability, Fair Value, Gross Liability	1	'	0
Other Liabilities b Noncurrent | Not Designated as Hedging Instrument [Member]	'	'	'
Derivative Liability, Fair Value, Gross Liability	$0	'	$0

Contingencies_Narrative_Detail

Contingencies (Narrative) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Sep. 30, 2013
In Millions, unless otherwise specified		Rejuvenate and ABG II Voluntary Recall [Member]	Electrical Network Communications, Hospital Beds [Member]	Patents Under Reexamination [Member]	Number of Remaining Patents [Member]	Minimum	Maximum	Zimmer Product Infringement [Member]
			patent	patent	patent	Rejuvenate and ABG II Voluntary Recall [Member]	Rejuvenate and ABG II Voluntary Recall [Member]
Loss Contingency Accrual, at Carrying Value	$80	'	'	'	'	'	'	'
Loss Contingency, Estimate of Possible Loss	'	'	'	'	'	1,130	1,580	'
Loss Contingency, Damages Awarded, Value	'	'	'	'	'	'	'	'228
Estimated Litigation Liability	'	$0	'	'	'	'	'	'
Loss Contingency, Number of Patents	'	'	9	6	3	'	'	'

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	PST	Other	MAKO	Trauson	Customer relationship	Customer relationship	Customer relationship
					PST	MAKO	Trauson
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Purchase price paid	$120	$172	$1,679	$751	'	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'	'	'	'	'14 years	'9 years	'15 years

Acquisitions_Acquisitions_Allo

Acquisitions Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of The Trauson Acquisition (Details) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
PST	'
Purchase price paid	$120
Inventory	7
Other assets	19
Liabilities	-33
Goodwill	68
Other	'
Purchase price paid	148
Inventory	5
Other assets	25
Liabilities	-32
Goodwill	74
MAKO	'
Purchase price paid	1,679
Inventory	50
Other assets	174
Liabilities	-277
Goodwill	1,217
Trauson	'
Purchase price paid	751
Inventory	43
Other assets	163
Liabilities	-87
Goodwill	450
Customer relationship | PST	'
Identifiable intangible assets:	33
Customer relationship | Other	'
Identifiable intangible assets:	4
Customer relationship | MAKO	'
Identifiable intangible assets:	91
Customer relationship | Trauson	'
Identifiable intangible assets:	112
Trade name | PST	'
Identifiable intangible assets:	0
Trade name | Other	'
Identifiable intangible assets:	0
Trade name | MAKO	'
Identifiable intangible assets:	24
Trade name | Trauson	'
Identifiable intangible assets:	34
Developed technology & patents | PST	'
Identifiable intangible assets:	26
Developed technology & patents | Other	'
Identifiable intangible assets:	70
Developed technology & patents | MAKO	'
Identifiable intangible assets:	231
Developed technology & patents | Trauson	'
Identifiable intangible assets:	31
IPRD | PST	'
Identifiable intangible assets:	0
IPRD | Other	'
Identifiable intangible assets:	2
IPRD | MAKO	'
Identifiable intangible assets:	169
IPRD | Trauson	'
Identifiable intangible assets:	$5

LongTerm_Debt_and_Credit_Facil2

Long-Term Debt and Credit Facilities (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Document Period End Date	31-Mar-14	'
Commercial paper	$500	'
Debt Instrument, Maturity	'397 days	'
Commercial paper	300	0
Commercial Paper, weighted average interest rate	0.30%	'
Line of Credit Facility, Remaining Borrowing Capacity	762	'
Long-term debt, weighted-average interest rate	2.70%	'
Unamortized Debt Issuance Expense	15	'
Debt Instrument, Fair Value Disclosure	2,792	2,790
3.00% senior unsecured notes, due January 15, 2015	'	'
Debt Instrument, Interest Rate, Stated Percentage	3.00%	'
Senior Unsecured Notes 2.00% due 2016 [Member]	'	'
Debt Instrument, Interest Rate, Stated Percentage	2.00%	'
1.30% senior unsecured notes, due April 1, 2018	'	'
Credit facility	600	'
Debt Instrument, Interest Rate, Stated Percentage	1.30%	'
Debt Instrument, Unamortized Discount	3	'
4.375% senior unsecured notes, due January 15, 2020	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%	'
4.10% senior unsecured notes, due April 1, 2043	'	'
Credit facility	400	'
Debt Instrument, Interest Rate, Stated Percentage	4.10%	'
Debt Instrument, Unamortized Discount	$6	'
Commercial paper	'	'
Debt Instrument, Maturity	'13 days	'

LongTerm_Debt_and_Credit_Facil3

Long-Term Debt and Credit Facilities (Maturities Of Long-Term Debt Disclosures) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Commercial paper	$300	$0
Other	'	25
Total debt	3,064	2,764
Less current maturities	-820	-25
Total long-term debt	2,244	2,739
3.00% senior unsecured notes, due January 15, 2015	'	'
Debt Instrument, Interest Rate, Stated Percentage	3.00%	'
Senior unsecured notes repayable in year three	500	500
4.375% senior unsecured notes, due January 15, 2020	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%	'
Senior unsecured notes repayable after year five	498	498
Senior Unsecured Notes 2.00% due 2016 [Member]	'	'
Debt Instrument, Interest Rate, Stated Percentage	2.00%	'
Long-term Debt, Maturities, Repayments of Principal in Year Three	749	749
1.30% senior unsecured notes, due April 1, 2018	'	'
Debt Instrument, Interest Rate, Stated Percentage	1.30%	'
Senior unsecured notes repayable in year four	598	598
4.10% senior unsecured notes, due April 1, 2043	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.10%	'
Senior unsecured notes repayable after year five	$395	$394

LongTerm_Debt_and_Credit_Facil4

Long-Term Debt and Credit Facilities Long-Term Debt and Credit Facilities (Parentheticals) (Details)	Mar. 31, 2014
3.00% senior unsecured notes, due January 15, 2015	'
Debt Instrument, Interest Rate, Stated Percentage	3.00%
4.375% senior unsecured notes, due January 15, 2020	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%
2.00% senior unsecured notes, due September 30, 2016	'
Debt Instrument, Interest Rate, Stated Percentage	2.00%
1.30% senior unsecured notes, due April 1, 2018	'
Debt Instrument, Interest Rate, Stated Percentage	1.30%
4.10% senior unsecured notes, due April 1, 2043	'
Debt Instrument, Interest Rate, Stated Percentage	4.10%

Capital_Stock_Narrative_Detail

Capital Stock (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014
Cash dividends declared, per share of common stock	$0.31	$0.27
Stock Repurchased and Retired During Period, Shares	0	0
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$683	'

Restructuring_Charges_Narrativ

Restructuring Charges (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Restructuring charges	$5	$14
Historical Restructuring Cost Per Year, Minimum	50	'
Historical Restructuring Cost Per Year, Maximum	75	'
Severance and Related Costs	'	'
Restructuring charges	3	'
Contractual Obligations and Other	'	'
Restructuring charges	$2	'

Company_Recorded_Restructuring

Company Recorded Restructuring Charges (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
January 1 Balance	$20	'
Charges to earnings	5	14
Cash paid	-8	'
Other adjustments	-1	'
March 31 Balance	16	'
Agent Conversions	'	'
January 1 Balance	2	'
Cash paid	-1	'
March 31 Balance	1	'
Severance and Related Costs	'	'
January 1 Balance	10	'
Charges to earnings	3	'
Cash paid	-4	'
Other adjustments	-1	'
March 31 Balance	8	'
Contractual Obligations and Other	'	'
January 1 Balance	8	'
Charges to earnings	2	'
Cash paid	-3	'
Other adjustments	'	'
March 31 Balance	$7	'

Segment_Information_Sales_And_

Segment Information (Sales And Other Financial Information By Business Segment) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net sales	$2,305	$2,190
Segment net earnings	131	386
Acquisition and integration related charges	-13	-17
Amortization of Intangible Assets, Net of Tax	-31	-23
Restructuring and related charges	-10	-11
Recall charges	-272	-32
Regulatory matter charges	'	-30
Tax Matters	-8	'
Net earnings	70	304
Reconstructive	'	'
Net sales	999	956
Segment net earnings	'	234
MedSurg	'	'
Net sales	886	837
Segment net earnings	'	161
Neurotechnology and Spine	'	'
Net sales	420	397
Segment net earnings	'	78
Total	'	'
Segment net earnings	480	473
Corporate and Other [Member]	'	'
Segment net earnings	($76)	($56)